The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
about
The miR-200 Family: Versatile Players in Epithelial Ovarian CancerSmall molecule compounds targeting miRNAs for cancer therapyMiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting BimUpregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathwayEpigenetic control of autophagy by microRNAs in ovarian cancerThe lncRNA n340790 accelerates carcinogenesis of thyroid cancer by regulating miR-1254LncRNA-TCONS_00026907 is involved in the progression and prognosis of cervical cancer through inhibiting miR-143-5pNanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinomaMiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.MicroRNAome genome: a treasure for cancer diagnosis and therapy.The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis.miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes.Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1.Metastasis of ovarian cancer is mediated by kallikrein related peptidases.miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.Long non-coding RNA GAS5 inhibits tumorigenesis via miR-137 in melanoma.The roles of microRNAs in neuroblastoma.Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.MicroRNA in Ovarian Biology and Disease.Non-coding RNA in Ovarian Development and Disease.MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancerMicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2.miRNAs and ovarian cancer: An overview.Long non-coding RNA DGCR5 is involved in the regulation of proliferation, migration and invasion of lung cancer by targeting miR-1180.Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge.Expression of miR-146a in patients with ovarian cancer and its clinical significance.Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195.A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells.MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3.LncRNA NEAT1 enhances the radio-resistance of cervical cancer via miR-193b-3p/CCND1 axis.miR‑205‑5p/PTK7 axis is involved in the proliferation, migration and invasion of colorectal cancer cells.Systems approach to identify environmental exposures contributing to organ-specific carcinogenesis.
P2860
Q26799353-3625EF32-E8BC-4D18-BC64-C78816BDEBEDQ26829982-1C1D115B-A856-437B-9C73-AB1A93BA0AEBQ28118859-59528AD6-333A-4F88-9165-3E7425D2B83FQ28539122-7DEB50E2-8F16-49CD-A5D2-1A820074A7C7Q33615837-895C4355-76AC-47E6-9569-C19451AB29DDQ33733127-EB675FC0-B631-4F35-94C1-3FF4560141F8Q33775216-9958FD42-3569-4507-B220-530737B74236Q34622662-760FEFCA-F14C-412F-8F7D-AC278966D65BQ34786575-6518396E-CB24-4D9B-88B2-AC0BE1C92758Q35068063-E476E407-EE3F-499A-980F-9DDCCA9E5B6DQ35704188-E2E7AF9B-FED9-48D4-A3FF-C9987B9E12F1Q35933934-832B3AEE-F20E-4539-A00D-AC4D8C614863Q36291106-2366C961-E2C7-4702-98F1-2A09C620108DQ37228217-25B872DB-6B46-444B-9D2C-A73583C81387Q37370429-1554E42C-C548-481B-81B4-A6CB3D2523E8Q37392708-FAF55CA1-210F-45B5-A190-B5BA3643D653Q37427776-4C9F1168-6366-4733-B256-38317F928745Q37480184-37A72B4C-A17C-4532-83F6-2B1E2E217351Q37697194-13BC3829-769D-4815-8B9E-028786946BFAQ37733036-BAF39C1C-9B0F-4EA9-8BE1-E887D5E06D19Q37733077-21E437E5-083B-4821-B720-61E67140EFFEQ38182012-82BA5190-5674-4EA3-98D2-3470C204BF20Q38256465-EFE3CB0C-01F0-4733-BE93-299EC7360BAFQ38489481-6B04D2CF-66F7-4B1E-8BDB-52027E28B0EBQ38667224-71AA953A-63CC-4152-AC97-5877534EA1FDQ38890397-B5C77434-C0C0-4F61-B294-B9A0B6B78C18Q38897001-D7AC27C2-150B-4788-82AE-8F63B067CF7CQ38916573-F4700015-5B53-411D-9FE2-F3E287F3F7DFQ39016879-691938A4-A460-45CF-BFD4-298D0E5E59DEQ39432311-4C86DCD9-DEDB-45C2-BD0C-8A70439C9A27Q41098244-0DE07425-61E0-4CD1-A942-DAEA049F79FCQ41233971-501DCDC8-EB7C-425F-979D-10CACC5DABDCQ41618429-32D2A6E3-4D3E-40AA-ACA4-AB509E946A62Q42316811-90EC48C5-97E6-4EFC-A673-2616381D0120Q47136784-5ACBDE39-5AAB-4D42-A74B-62B92901B3FAQ47138409-F9029E56-4621-4134-BFCE-13AE7635233CQ49501127-0EC7BFFC-9834-43EC-A221-93A0DC1E58FCQ49996731-10165A39-B8B3-4830-A114-C7A345DAC19CQ50421596-612A4AD1-6A86-4D61-B57D-02F066817061Q53239473-1CA9AD40-5DC3-4F00-8D56-71B7C3CB9229
P2860
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
@en
type
label
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
@en
prefLabel
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
@en
P2860
P356
P1476
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer.
@en
P2093
Gianpiero Di Leva
P2860
P356
10.3389/FONC.2013.00153
P577
2013-06-13T00:00:00Z